Urologic oncology is the medical subspecialty focused on diagnosing and treating cancers that develop in the urinary tract and male reproductive organs. That includes cancers of the prostate, bladder, kidneys, testicles, and penis. These are among the most common cancers overall: in 2025, an estimated 313,780 new prostate cancer cases, 84,870 bladder cancer cases, and 80,980 kidney cancer cases will be diagnosed in the United States alone.
What a Urologic Oncologist Does
A urologic oncologist is a surgeon who completed a urology residency and then pursued an additional two-year fellowship specifically in cancer surgery and management. That extra training matters because urologic cancers span a wide range of complexity. Some tumors can be safely monitored for years without treatment. Others require intricate surgery to remove a tumor while preserving organ function, fertility, or urinary control. A urologic oncologist’s role is to determine which approach fits each patient’s situation and to perform the procedures that follow from that decision.
General urologists handle many common urologic conditions, including early-stage cancers. But when a cancer is aggressive, has spread beyond its original site, or requires a technically demanding operation, patients are typically referred to a urologic oncologist. The distinction is important because treatment recommendations can vary depending on a specialist’s training. One study comparing how urologists and radiation oncologists approached localized prostate cancer found that each group overwhelmingly favored the therapy they themselves deliver. Urologic oncologists, trained across surgical and nonsurgical options, are positioned to weigh those choices for more complex cases.
Prostate Cancer: Surveillance and Surgery
Prostate cancer is the single largest part of urologic oncology practice. Not every prostate cancer needs immediate treatment. For low-risk tumors, a strategy called active surveillance allows patients to avoid surgery or radiation while being closely monitored with regular blood tests, imaging, and biopsies. Most guidelines reserve this approach for men whose PSA level is below 10 and whose biopsy shows a Gleason score of 6 or lower, meaning the cancer cells still look relatively normal under a microscope. A few guidelines extend eligibility to men with a Gleason score of 3+4 (a slightly higher grade), but this is less common.
When surgery is needed, robotic-assisted prostatectomy has become the dominant technique. Compared to traditional open surgery, robotic surgery reduces blood loss substantially. One large comparison found that estimated blood loss averaged about 228 milliliters with robotic assistance versus 852 milliliters with open surgery. Transfusion rates reflected this gap: roughly 3% of robotic patients needed a blood transfusion compared to about 20% of open surgery patients. Hospital stays are also shorter, averaging around 3 days for robotic procedures versus 6 days for open ones.
MRI-Based Risk Scoring
Before deciding on treatment, urologic oncologists increasingly use a specialized MRI scan to evaluate suspicious prostate lesions. Radiologists assign each lesion a score from 1 to 5 on a standardized scale. A score of 1 means clinically significant cancer is highly unlikely, while a score of 5 means it’s highly likely. The cancer detection rates at each level tell a clear story: lesions scored as 1 or 2 harbor significant cancer only about 2 to 4% of the time. A score of 3 is considered equivocal, with about a 20% detection rate. Scores of 4 and 5 jump to roughly 52% and 89%, respectively. This scoring helps urologic oncologists decide which patients truly need a biopsy and which can be spared one.
Bladder Cancer Treatment
Bladder cancer that hasn’t invaded the muscle wall of the bladder is typically treated with a procedure to shave off the visible tumor, followed by a course of immunotherapy delivered directly into the bladder through a catheter. The standard protocol uses a weakened form of a tuberculosis bacterium (BCG) to stimulate the immune system to attack remaining cancer cells. Treatment starts with six weekly instillations, followed by a shorter three-week maintenance course.
The effectiveness of this approach depends heavily on whether patients complete the maintenance phase. With just the initial six-week course, recurrence-free survival ranges from 25 to 74%. Adding maintenance therapy reduces recurrence by an additional 28% compared to induction alone. For a specific type of early bladder cancer called carcinoma in situ, completing both phases pushed the complete response rate from 69% to 84%. When BCG fails or the cancer invades deeper into the bladder wall, urologic oncologists may recommend removing the entire bladder, a major operation that also involves creating a new way for the body to store and pass urine.
Kidney Cancer: Saving the Organ
The guiding principle in kidney cancer surgery has shifted dramatically over the past two decades. Rather than removing the entire kidney by default, urologic oncologists now aim to remove only the tumor and a thin margin of healthy tissue whenever technically possible. This organ-sparing approach, called partial nephrectomy, preserves kidney function and lowers the long-term risk of kidney disease.
Tumor size is the primary factor in deciding between partial and full kidney removal. Tumors 4 centimeters or smaller (classified as T1a) are strong candidates for partial removal, and current European guidelines recommend it as the first choice. Tumors between 4 and 7 centimeters (T1b) should also be treated with partial nephrectomy when the surgeon judges it feasible. The location of the tumor within the kidney, its proximity to major blood vessels, and the patient’s overall kidney health all factor into whether a partial approach is safe. Much of this surgery is now performed robotically, offering the same advantages of reduced blood loss and faster recovery seen in prostate procedures.
Testicular Cancer Outcomes
Testicular cancer stands out in oncology for its exceptionally high cure rates, even when the disease has spread. Based on data from 2015 to 2021, the five-year survival rate for testicular cancer caught while still confined to the testicle is 99%. When it has spread to nearby lymph nodes (regional stage), survival remains 96%. Even for distant-stage disease that has reached the lungs or other organs, the five-year survival rate is 72%.
Treatment typically begins with surgical removal of the affected testicle. Depending on the cancer type and stage, urologic oncologists may then recommend surveillance alone, chemotherapy, radiation, or a specialized lymph node surgery in the abdomen. The choice depends on whether the cancer is a seminoma or nonseminoma (the two main types), and whether there are signs of spread on imaging. For many early-stage patients, surgery alone is curative, with chemotherapy held in reserve if the cancer returns.
Penile Cancer
Penile cancer is rare but falls squarely within urologic oncology. Treatment depends on tumor size and depth. Small, superficial lesions can sometimes be treated with laser therapy or topical treatments that preserve the organ. Larger or deeper tumors may require partial or total removal of the penis, along with evaluation of the lymph nodes in the groin. Because of its rarity, penile cancer is best managed at specialized centers where urologic oncologists see enough cases to maintain expertise in both surgical technique and reconstruction.